NOD2 and lung cancer: Researchers discovered that inhibiting NOD2 improved the chemotherapeutic sensitization of nonsmall-cell lung cancer (NSCLC) to paclitaxel in Lewis lung carcinoma (LLC) tumor-bearing mice [41].